Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Hepatology. 2007 Aug;46(2):388-94.

PMID:
17604363
2.

[HBV genotype and liver histology effect of peginterferon alpha treatment of HBeAg-position chronic hepatitis B].

Lu CT, Gao GS, Yan HD, Hu YR.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Jun;27(3):193-5. Chinese.

PMID:
24319954
3.

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.

N Engl J Med. 2005 Jun 30;352(26):2682-95.

4.

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, Choi PC, Chan AW, Sung JJ, Chan HL.

Hepatology. 2010 Jun;51(6):1945-53. doi: 10.1002/hep.23568.

PMID:
20209602
5.

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.

Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL.

Gastroenterology. 2008 Aug;135(2):459-67. doi: 10.1053/j.gastro.2008.05.031. Epub 2008 May 15.

PMID:
18585385
6.

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.

van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Liver Int. 2006 May;26(4):399-405.

PMID:
16629642
7.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

N Engl J Med. 2004 Sep 16;351(12):1206-17.

8.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL.

Gastroenterology. 2009 Dec;137(6):2002-9. doi: 10.1053/j.gastro.2009.08.061. Epub 2009 Sep 6.

PMID:
19737568
9.

The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.

Dogan UB, Golge N, Akin MS.

Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1312-6. doi: 10.1097/MEG.0b013e328362389a.

PMID:
23652913
10.
11.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.

Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

Gut. 2007 May;56(5):699-705. Epub 2006 Nov 24.

12.

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.

Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.

Am J Gastroenterol. 2005 Nov;100(11):2463-71.

PMID:
16279901
13.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
14.

Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.

Zhu H, Wang C, Zhang Y, Wei S, Li X, Zhang Z.

J Gastroenterol Hepatol. 2016 Dec;31(12):1963-1970. doi: 10.1111/jgh.13414.

PMID:
27075693
15.

HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo.

Hansen BE, Rijckborst V, Ter Borg MJ, Janssen HL.

J Med Virol. 2011 Nov;83(11):1917-23. doi: 10.1002/jmv.22208.

PMID:
21915866
16.

[Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].

Lu HY, Zhuang LW, Yu YY, Si CW, Li J.

Zhonghua Gan Zang Bing Za Zhi. 2008 Mar;16(3):198-202. Chinese.

PMID:
18364079
17.

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.

Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Am J Gastroenterol. 2006 Feb;101(2):297-303.

PMID:
16454834
18.

Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.

Keating GM.

Drugs. 2009;69(18):2633-60. doi: 10.2165/11203660-000000000-00000. Review.

PMID:
19943712
19.

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research.

Lancet. 2005 Jan 8-14;365(9454):123-9.

PMID:
15639293
20.

[Liver histopathological features influencing HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B responding to Peg-IFN treatment].

Yan HD, Jiang FR, Zhu CL, Gao GS, Weng PJ, Hu AR, Xu CF, Hu YR, Sheng JF.

Zhonghua Gan Zang Bing Za Zhi. 2013 May;21(5):340-4. doi: 10.3760/cma.j.issn.1007-3418.2013.05.007. Chinese.

PMID:
24025133

Supplemental Content

Support Center